

# CITATION REPORT

List of articles citing

Variability of intended copies for etanercept (Enbrel ):  
Data on multiple batches of seven products

DOI: 10.1080/19420862.2017.1387346  
MAbs, 2018, 10, 166-176.

**Source:** <https://exaly.com/paper-pdf/69603534/citation-report.pdf>

**Version:** 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
18	Evaluation of analytical similarity between trastuzumab biosimilar CT-P6 and reference product using statistical analyses. <i>MAbs</i> , <b>2018</b> , 10, 547-571	6.6	24
17	Review of biologics, biosimilars, and intended copies in rheumatology, and current practice in Iraq. <i>Open Access Rheumatology: Research and Reviews</i> , <b>2019</b> , 11, 1-9	2.4	
16	Biosimilars in oncology and inflammatory diseases: current and future considerations for clinicians in Latin America. <i>MAbs</i> , <b>2018</b> , 10, 827-842	6.6	3
15	Practical Guidance on Biosimilars, With a Focus on Latin America: What Do Rheumatologists Need to Know?. <i>Journal of Clinical Rheumatology</i> , <b>2019</b> , 25, 91-100	1.1	6
14	[Biosimilar monoclonal antibodies: comparative study of analytical and functional quality]. <i>Medecine/Sciences</i> , <b>2019</b> , 35, 1146-1152		1
13	Orthogonal Middle-up Approaches for Characterization of the Glycan Heterogeneity of Etanercept by Hydrophilic Interaction Chromatography Coupled to High-Resolution Mass Spectrometry. <i>Analytical Chemistry</i> , <b>2019</b> , 91, 873-880	7.8	21
12	Demystifying biosimilars: development, regulation and clinical use. <i>Future Oncology</i> , <b>2019</b> , 15, 777-790	3.6	13
11	Rapid methodology for basal system selection of therapeutic proteins during the early stage biopharmaceutical development. <i>Journal of Pharmaceutical Investigation</i> , <b>2020</b> , 50, 363-372	6.3	2
10	Etanercept biosimilar (recombinant human tumor necrosis factor- $\alpha$ receptor II: IgG Fc fusion protein) and methotrexate combination therapy in Chinese patients with moderate-to-severe plaque psoriasis: a multicentre, randomized, double-blind, placebo-controlled trial. <i>Archives of Dermatology</i> , <b>2020</b> , 156, 107-115	3.3	6
9	Functional analysis of glycosylation in Etanercept: Effects over potency and stability. <i>European Journal of Pharmaceutical Sciences</i> , <b>2020</b> , 153, 105467	5.1	1
8	Reporting of quality attributes in scientific publications presenting biosimilarity assessments of (intended) biosimilars: a systematic literature review. <i>European Journal of Pharmaceutical Sciences</i> , <b>2020</b> , 154, 105501	5.1	3
7	Cost-Effectiveness of Tofacitinib for Patients with Moderate-to-Severe Rheumatoid Arthritis in China. <i>Pharmacoeconomics</i> , <b>2020</b> , 38, 1345-1358	4.4	7
6	Batch-to-Batch Consistency of SB4 and SB2, Etanercept and Infliximab Biosimilars. <i>BioDrugs</i> , <b>2020</b> , 34, 225-233	7.9	4
5	Nonmedical Switching From Originators to Biosimilars: Does the Nocebo Effect Explain Treatment Failures and Adverse Events in Rheumatology and Gastroenterology?. <i>Rheumatology and Therapy</i> , <b>2020</b> , 7, 35-64	4.4	29
4	Anti-TNF biosimilars in rheumatology: the end of an era?. <i>Expert Opinion on Biological Therapy</i> , <b>2021</b> , 21, 29-36	5.4	2
3	Therapeutic Fc-fusion proteins: Current analytical strategies. <i>Journal of Separation Science</i> , <b>2021</b> , 44, 35-62	3.4	26
2	Biologic Drugs for Rheumatoid Arthritis in the Context of Biosimilars, Genetics, Epigenetics and COVID-19 Treatment. <i>Cells</i> , <b>2021</b> , 10,	7.9	7

- 1 Analytical Similarity Assessment of Biosimilars: Global Regulatory Landscape, Recent Studies and Major Advancements in Orthogonal Platforms.. *Frontiers in Bioengineering and Biotechnology*, **2022**, 10, 832059 5.8 3